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Objective: The role of en bloc esophagectomy in the surgical treatment of 
patients with locally advanced esophageal cancer is not well defined. This 
report attempts to elucidate its impact on survival, in comparison with less 
extensive resection, among patients with stage III disease. Methods: A 
prospectively established database was retrospectively analyzed. Results: 
One hundred twenty-eight patients underwent esophagectomy for carci- 
noma of the thoracic esophagus between 1988 and 1996 (78 underwent en 
bloc resection and 50 underwent standard resection). The 30-day and 
hospital mortality rates were 3.9% and 5.4%, respectively, comparable for 
the two procedures. Fifty-four patients had stage IlI disease. Overall 4-year 
survival was 34.5% after en bloc resection, with a median survival of 27 
months (n = 33), and 11% after standard resection (n = 21), with a median 
survival of 12 months (p = 0.007). Among patients with stage III disease 
undergoing a complete resection, 4-year survivals were 36.7% and 0% after 
en bloc and standard resections, respectively (p = 0.001). Eighty-six of 128 
patients had nodal metastasis. Three-year survivals for patients with N1 
disease were 33.9% and 13% after en bloc and standard resections, 
respectively (p = 0.02). Conclusion: Among patients with stage III esopha- 
geal cancer, en bloc resection appears to significantly improve survival 
compared with lesser resections. This improvement in survival may be 
attributable to resection of nodal disease. (J Thorac Cardiovasc Surg 1997; 
114:948-56) 
A s the century draws to an end, the prospects of prolonged survival for patients with esophageal 
carcinoma remain as dismal as they were nearly 40 
years ago. The poor prognosis of this disease per- 
sists, despite the significant refinements in operative 
techniques, refinements in perioperative care, and 
the introduction of various neoadjuvant modali- 
ties. 1-3 The dramatic and continuing increase in the 
incidence of adenocarcinoma of the esophagus and 
cardia lends urgency to the development of im- 
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proved therapeutic strategies for this disease. 4'5 The 
past decade has witnessed an ongoing worldwide 
debate among surgeons regarding the need for and 
the efficacy of radical esophageal resections, with 
most favoring more limited transthoracic or trans- 
hiatal resections. 6-s Advocates of these latter ap- 
proaches argue that esophageal carcinoma, once 
diagnosed, is a systemic disease, and palliation 
rather than cure should therefore dictate the oper- 
ative strategy. 6 A few surgical groups, ourselves 
included, have advocated a more radical resection in 
the hope of altering the natural history of the 
disease in patients with limited nodal metastasis. TM
In fact, since 1986 we have favored en bloc esoph- 
agectomy for patients with stage I or II esophageal 
carcinoma, resorting to a more limited resection 
when preoperative or intraoperative staging sug- 
gests more advanced isease. 12 This approach was 
rooted in our belief that the more extensive n bloc 
resection might not be justified given the unlikely 
possibility of improving survival among patients with 
stage III disease. Interestingly, however, an interim 
analysis of our results in 1992 suggested that the 
morbidity and mortality for radical and less exten- 
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sive resections were, at least in our experience, 
similar. We therefore altered our surgical strategy as 
of June 1992, and we have since per formed en bloc 
resect ion in pat ients with all stages of esophageal  
carcinoma, with the obvious exceptions of  those with 
visceral metastasis or T4 lesions. This report  ana- 
lyzes the outcome of this strategy in this group of 
patients. 
Methods 
Between January 1988 and September 1996, 128 
patients with carcinoma of the thoracic esophagus 
underwent surgical resection at The New York Hospi- 
tal-Cornell  Medical Center. All patients underwent a
preoperative diagnostic and staging evaluation that 
included an esophagogastroduodenoscopy, a computed 
tomographic scan of the chest and upper abdomen, and 
br0nchoscopy in patients with tumors of the upper and 
middle thirds. Endoscopic ultrasonography was used in 
a significant number of cases; however, its utility in 
clinical decision making was restricted to determining 
which patients had T4 lesions and were not considered 
operative candidates. Patients were evaluated for their 
overall performance status according to standard East- 
ern Cooperative Oncology Group (ECOG) criteria 
(Table I). Additionally, all patients underwent evalua- 
tion of pulmonary and cardiac function to determine 
their ability to withstand the planned procedure. Gen- 
erally, patients with a forced expiratory volume in 1 
second of less than 1.5 L despite aggressive physiother- 
apy and bronchodilator therapy were considered ineli- 
gible for resection, but decisions were made individu- 
ally, depending on the stage of the disease and the 
presence of other comorbid factors. Any cardiac disease 
was carefully evaluated, up to and including coronary 
angiography in selected cases. Preoperative cisplatin- 
based chemotherapy was used in nine patients, five of 
whom underwent an en bloc resection and four of 
whom underwent a standard resection. 
Surgical procedures. Before June 1992, patients were 
selected to receive an en bloc resection if preoperative or
intraoperative staging predicted stage I or II disease. If 
staging maneuvers suggested transmural disease with ob- 
vious nodal metastasis or celiac nodal disease, or if 
visceral metastasis was unexpectedly encountered, then a 
standard resection was performed. Since June 1992, all 
patients have undergone n bloc resection unless intraop- 
erative exploration revealed unexpected visceral metasta- 
sis, in which case a standard resection was done. 
For tumors of the gastroesophageal junction and the 
lower and middle thirds of the esophagus, an en bloc 
resection was accomplished by excision of the tumor 
within a wide envelope of surrounding tissue including 
both pleural surfaces laterally, the pericardium anteriorly, 
and the thoracic duct posteriorly. For tumors that tra- 
versed the hiatus, the envelope of tissue included a 1-inch 
circumferential cuff of diaphragm as well. The ensuing 
lymph node dissection included all lymphatic and areolar 
tissue between the tracheal bifurcation and the celiac axis, 
including the retroperitoneal, common hepatic, and 
Table I. ECOG performance scale 
Grade Description 
Normal activity 
Showing symptoms of disease, but ambulatory and 
able to carry out activities of daily living 
Out of bed more than 50% of time; occasionally 
needs assistance 
In bed more than 50% of time; needs nursing care 
Bedridden; may need hospitalization 
splenic nodal tissue. Upper-third tumors were resected 
within the constraints imposed by the narrow confines of 
the superior mediastinum; however, excision Of the tho- 
racic duct and the previously described lymphadenectomy 
were performed in every case. In 32 patients, the lymph- 
adenectomy was extended to include the nodes along both 
recurrent nerves as well as the deep cervical lymph nodes 
(three-field lymphadenectomy). When less extensive re- 
sections were performed, the tumor-bearing esophagus 
was resected along with the periesophageal, parahiatal, 
and left gastric nodal chains. No attempt was made to 
resect the thoracic duct or perform a retroperitoneal 
dissection of the upper abdomen. Regardless of the type 
of resection, the gastrointestinal tract was divided with 8 
to 10 cm proximal and distal margins. 
Resections were considered curative when no gross 
residual disease was left behind at the conclusion of the 
procedure or found by frozen-section examination of the 
surgical margins of resection (Ro). Resections were con- 
sidered palliative if microscopic disease (R~) or residual 
gross tumor (R2) were present either at the margins of 
resection or within the mediastinum or upper abdomen. 
The use of the R descriptors decreases the element of 
subjectivity in determining the curative or palliative na- 
ture of a given procedure. 
Reconstruction. Alimentary tract continuity was re- 
stored with a greater curvature gastric tube in 112 patients 
and a colon interposition in 15. Reconstruction was 
delayed in one patient who underwent a cervical esopha- 
gostomy and gastrostomy. Forty anastomoses were lo- 
cated in the mediastinum and 87 were located in the neck. 
Follow-up. Most patients were seen at 3-month inter- 
vals during the first 2 years, every 6 months for the next 
year, and yearly thereafter. Patients referred from distant 
geographic locations were followed up by their local 
physicians. Follow-up was obtained in such instances 
either by direct physician contact or patient contact. 
Statistical analysis. Survival time was measured as the 
time from the procedure until death (including operative 
death) or until last (most recent) follow-up. Survival 
distribution was estimated by the product-limit method 
and compared by the log-rank test. The confidence inter- 
val (CI) around the probability of survival is symmetric 
and was calculated by taking twice the standard error and 
adding or subtracting from the point estimate to obtain 
the upper and lower bounds of the interval. The CI 
around median survival time is not necessarily symmetric 
(a well-known property of CIs around medians). The 
upper limit of the CI may not be calculable for certain 
patterns of data (e.g., when the number of "events" after 
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Table I I .  Mortality and morbidity 
Standard En bloc 
resection resection Total 
(n = 50 ) (n = 78) (n = 128) 
In-hospital death 3 (6%) 4 (5.1%) 
Complications 
Respiratory 13 (26%) 19 (24%) 32 (25%) 
Pneumonia 2 4 
Prolonged intubation 10 13 
Tracheostomy 2 5 
Atelectasis* 2 6 
Cardiac 4 (8%) 3 (3.8%) 7 (5.4%) 
Myocardial infarction 1 - -  
Arrhythmiat 2 2 
Pericarditis 1 1 
Leaks 8 (16%) 10 (12.8%) 18 (14%) 
Recurrent nerve injury 1 (2%) 3 (3.8%) 4 (3%):) 
Chylothorax 2 - -  2 (1.5%) 
Infection 4 6 10 
Bleeding - -  2 2 
Other 
Pancreatitis 1 
Bowel obstruction 1 - -  
Delirium tremens - -  3 
*Requiring bronchoscopy. 
tHemodynamically significant. 
:~Two permanent, two transient. 
Table II1. Staging, pTMN 
En bloc Standard 
Total (n = 78) (n = 50) 
T/N status 
Tis 4 4 0 
T1 16 15 1 
T2 22 15 7 
T3 77 41 36 
T4 9 3 6 
NO 42 31 11 
N1 86 47 39 
p TNM 
Stage 0 4 4 - -  
Stage I 14 13 1 
Stage IIA 20 13 7 
Stage IIB 13 9 4 
Stage III 54 33 21 
Stage IV 23 6 17 
M1 (lymph) 5 12 
M1 (organ) 1 5 
the median survival estimate isdisproportionately small in 
comparison to the number of Censored observations). 13'14 
Comparisons between the standard and en bloc proce- 
dures for patients with stage III disease were done by the 
two-sample t test for ordinal variables (e.g., age, tumor 
size) and by Fisher's Exact Test (or)(2 test where appro- 
priate) for categoric variable s (e.g., sex, cell type). All tests 
were performed at a 0.05 significance level, with no 
adjustments for multiple testing. 
Results 
One hundred twenty-eight patients underwent 
esophagectomy for carc inoma of the thoracic esoph- 
agus. There were 101 male and 27 female patients, 
with a median age of 62 (range 38 to 87) years. Al l  
pat ients had an ECOG performance status of 0 to 2. 
Tumors were located in the lower third of the 
thoracic esophagus (below the level of the inferior 
pulmonary vein) in 86 patients and precisely at the 
gastroesophageal  junct ion in 16 patients. Twenty- 
one patients had middle-th i rd tumors, whereas in 
five the tumors were located above the tracheal 
bifurcation. En bloc esophagectomy was per formed 
in 78 patients, 32 of whom also underwent a three- 
field lymph node dissection. Fifty pat ients under-  
went a less extensive resection, pr imari ly by a trans- 
thoracic route. Resect ions were considered curative 
(Re) in 113 cases (37 standard, 76 en bloc), Resec- 
tions were pall iative in 15 cases (2 en bloc, 13 
standard) because of the presence of residual tumor  
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Table IV. Survival by stage for en bloc versus tandard resection 
Standard resection 
Median surv 
n 4 yr surv (%) (rno) n 
En bloc resection 
4 yr surv (%) Median surv (mo) p Value 
Stage I 1 ~ - -  13 
Stage I1 11 13 20 (15-29) 22 
Stage III 
All resections 21 11 (0-25) 12.6 (8-14) 33 
R 0 resections 16 0 (0-22) 12 (8-14) 31 
71.9 - -  - -  
32.9 38 (23-?)* 0.02 
34.5 (12-56) 27 (17-?)* 0.007 
36.7 (12-60) 27.3 (17-?)* 0.001 
The 95% CIs are given in parentheses• surv, Survival. 
*Upper limit of CI could not be computed. 
(R 1 or R2) at the conclusion of the procedure. 
Resection was considered incomplete because of the 
presence of distant visceral metastasis n six cases. 
unresectable nodal disease in seven, and positive 
esophageal margins in two. 
In,hospital mortality rate. The overall in-hospi- 
tal mortality rate was 5.4%, with seven in-hospital 
deaths (30-day mortality rate of 3.9%). There were 
four deaths in the en bloc group (5.1%) and three in 
the limited-resection group (6%). 
Operative morbidity. Seventy three patients 
(57%) had uncomplicated postoperative courses. 
Complications occurred in 55 patients, for an oper- 
ative morbidity of 43%. Respiratory complications 
and anastomotic leaks were the most common mor- 
bidities for both procedures (Table II). 
Pathology and postsurgieal staging. There were 
38 squamous cell carcinomas and 90 adenocareino- 
mas. Tumors were considered well differentiated in 
18 cases, moderately differentiated in 43. and poorly 
differentiated in 67. Staging was based on the TNM 
staging system of the American Joint Committee on 
Cancer (Table III). Overall. there were four patients 
with stage 0 disease, 14 with stage I, 20 with stage 
IIA, 13 with stage IIB. and 54 with stage III. 
Twenty-three patients had stage IV disease: six had 
distant visceral metastases and 17 were found to 
have stage IV disease on the basis of cancer metas- 
tasis to the celiac or cervical nodes. Overall. 86 
patients (68%) had node-positive disease. 
Actuarial survival. Follow-up was complete for 
100% of patients until death or April 1997. Over- 
all survival was 25% for all 128 patients, including 
operative deaths. Four-year survival for the 50 
patients undergoing limited resection was 8% 
(95% CI 0% to 18%), compared with 41.5% (95% 
CI 25-57%) for the en bloc group. For patients 
with curative resections (R0), 4-year survival and 
median survival after en bloc resections were 
42.5% (95% CI 26% to 58%) and 38 months, 
respectively, versus 11.4% (95% CI 0% to 20%) 
and 13.8 months after standard resections (p = 
0.0002, log-rank). Although these differences 
were statistically significant, they were at least 
partly caused by the selection of all patients with 
stage 0 and stage I disease to receive en bloc 
resection and resorting to standard resections for 
most patients with stage IV disease. 
Thirteen patients with stage I disease and four 
patients with stage 0 (TisN0) underwent en bloc 
resection. Their survivals at 4 years were 75% and 
100%, respectively. Only one patient with stage I
disease underwent a standard resection. Patients 
with stage IIA and liB disease were grouped to- 
gether for survival analysts because of their rela- 
tively small numbers. Survival of patients with stage 
II disease is shown in Table IV and seems to favor 
the en bloc group (p = 0.02, log-rank). 
Fifty-fou r patients had stage III disease; 33 of 
these underwent en bloc esophagectomy and 2! 
underwent a limited resection. Four-year survival 
and median survival for the limited-resection group 
were 1i% and 12 months, respectively. After en bloc 
resection, the 4-year survival rate was 34.5%, with a 
median of 27 months (Table IV, Fig. 1). This 
improvement in survival by en bloc resection for 
patients with stage III disease was statistically sig- 
nificant when compared with survival after standard 
resection (p = 0.007, log-rank). Thirty-one patients 
had a curative en bloc resection, with a 4-year 
survival rate of 36.7% (median 27 months). Sixteen 
patients had a curative standard resection, with no 
4-year survivors (median 12 months) (p = 0.001, 
log-rank; Fig. 2). 
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Because most retrospective analyses of this type 
carry an inherent selection bias, we compared both 
groups for several criteria that might have unduly 
favored the en bloc resection group (Table V). 
There were no statistically significant differences 
between the groups in age, sex, tumor cell type or 
differentiation, and patient performance status. Al- 
though Patients in the limited-resection group 
tended to have larger tumors (4.5 vs 3.7 cm) and 
patients in the en bloc group tended to have more 
positive nodes per patient (4.1 vs 3.5), these differ- 
ences did not attain statistical significance. 
Forty-two patients had node-negative disease. 
Thirty:one underwent en bloc resection and 11 
underwent limited resection. Survival rates for pa- 
tients with node-negative disease are shown in Table 
VI. The mean number of resected nodes in the 
patients with node-negative disease was 35.9 nodes/ 
patient for en bloc resection and 19.5 nodes/patient 
for limited resection (p = 0.03). Eighty-six patients 
had metastatic arcinoma in their lymph nodes. 
Three-year survival for 47 patients who underwent 
en bloc resection was 33.9% (median 23 months). 
For patients with node-positive disease who under- 
went limited resection (n = 39), the corresponding 
survival figure was 13% (median 12.6 months; Fig. 3, 
Table VI). These differences in survival were statis- 
tically significant, with a p value of 0.002 by the 
log-rank test. The mean number of positive nodes 
per patient was slightly higher for the limited- 
resection group (5 positive nodes/patient) compared 
with the en bloc group (4.1 positive nodes/patient); 
however, the difference was not statistically signifi- 
cant (p = 0.22). 
Discussion 
The results of this study seem to support our 
current recommendation that en bloc esophagec- 
tomy be offered to patients with stage I, II, and 
III esophageal cancer who are considered candi- 
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Table V. Analysis of variance for patients with stage III disease: Enbloc versus tandard resection 
Standard (n = 21) Enbloc (n = 33) p Value Test 
Age (yr) 63.8 _+ 13" 58.5 _+ 8.91" 0.07 t test 
Sex 17 male, 4 female 29 males, 4 females 0.69 Fisher's Exact Test 
Cell type 12 adenocarcinoma, 9 squamous 24 adenocarcinoma, 9 squamous 0.17 X z 
cell carcinoma cell carcinoma 
Differentiation 1 well, 6 moderate, 14 poor 2 well, 7 moderate, 24 poor 0.885 Fisher's Exact Test 
ECOG status 20 status 1, 1 status 2 1 status 0, 32 status 1 0.63 Fisher's Exact Test 
Tumor size (cm) 4.5 _+ 2.15" 3.7 _+ 1.71" 0.1 Student test 
Positive nodes/patient 3.5 _+ 3.26* 4.1 _+ 2.82* 0.4 Student test 
Table VI. Survival by nodal status for en bloc versus standard resection 
Standard resection En bloc resection 
N status n 3 yr surv (%) Median surv (too) n 3 yr surv (%) Median surv (mo) p Value 
NO 11 27 (0-59) 28 (8.6-50.0) 31 68 (46-90) NR (38-?)* 0.01 
N1 39 13 (1-25) 12 (10.0-15.0) 47 33.9 (14-53) 23 (20-47) 0.002 
The 95% CIs are given in parentheses, surv, Survival; NR, not reached. 
*Upper limit of CI could not be computed. 
dates for curative (R0) surgical resection. In our 
view, this strategy is supported by four basic 
arguments. 
First, the more extensive lymphadenectomy of- 
fered by the en bloc technique allows better staging, 
as evidenced by the improved survival among pa- 
tients with node-negative disease treated by en bloc 
resection compared with similar patients undergo- 
ing a more standard resection. Undoubtedly, a
significant number of the latter group had their 
disease understaged; their inferior survival cannot 
be explained otherwise. The understaging of disease 
in patients receiving less extensive procedures has 
been shown previously by other investigatotsJ s' 16 
Akiyama nd colleagues 16reported that the survival 
of patients without nodal metastasis was 83.9% after 
three-field issection compared with 55% for pa- 
tients treated by a two-field lymphadenectomy. We 
recently reported our own preliminary experience 
with three-field lymphadenectomy for squamous cell 
carcinoma nd adenocarcinoma of the esophagusJ 7 
The prevalence of nodal metastasis in that series of 
patients was 73%, compared with 68% in this report. 
Significantly, however, 20% of patients with nega- 
tive nodes in the mediastinum and abdomen had 
nodal metastasis in the cervical or recurrent laryn- 
geal nodes. These data, as well as those of such 
others as Akiyama and colleagues, 16 strongly imply 
that understaging is directly related to the extent of 
the lymphadenectomy performed. 
Second, although the presence of nodal metasta- 
sis undoubtedly results in diminished survival, pro- 
longed survival and even cure may occasionally be 
possible after extended lymphadenectomy. Lieber- 
man and associates is reported a 3-year survival of 
37% among 87 patients in whom nodal metastasis 
was limited to one to three nodes. Additionally, 
Akiyama and colleagues 16reported a 28% 5-year 
survival among patients with positive nodes after 
esophagectomy with radical mediastinal nd abdom- 
inal lymphadenectomy. Impressively, several Japa- 
nese surgeons have recently reported 5-year survival 
rates in the 20% range after three-field issection 
for patients in whom metastatic carcinoma extended 
to the cervical nodes. 15' 16, 19 Although these latter 
results have yet to be reproduced outside Japan, 
they suggest that at least in a subset of patients, the 
disease remains localized and therefore potentially 
curable. In this report, the survival of patients with 
N1 disease treated by en bloc resection was 34% at 
3 years, compared with only 13% for those treated 
by more limited resections. The groups appear 
reasonably similar, because the mean number of 
positive nodes per patient was not significantly 
different for the two procedures. It thus appears 
that, contrary to commonly held belief, resection of 
nodal metastasis may favorably affect survival and 
may even be curative for some patients. One caveat, 
however, is the relatively short follow-up period in 
this report, because we have begun to encounter 
recurrences as late as 30 to 36 months after resec- 
tion. It is concievable that a more radical resection 
simply shifts the survival curve toward the right, 
without having a major impact on "cure" rates. 
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Third, and perhaps most significantly, the results 
after en bloc resection in patients with stage III 
disease reported here may increase the chances of 
prolonged survival in the substantial number of 
patients initially seen with this disease stage. Sur- 
vival at 4 years was 34% after en bloc resection 
compared with 11% after limited resection. The 
improvement in survival after en bloc resection was 
evident, even when only patients with curative re- 
sections were considered. Within the constraints of 
this retrospective analysis, we could not detect any 
nonexperimental f ctor that might have imparted a
survival advantage to the en bloc group. Both groups 
had similar demographic features, pathologic har- 
acteristics, and performance statuses. The tenden- 
cies toward larger tumors in the standard resection 
group and toward more positive nodes per patient in 
the en bloc group did not prove to be of statistical 
significance. Additionally the 11% 4-year survival 
after limited resection in this report is basically 
within the range of survival rates reported by others 
for stage III esophageal cancer. Lieberman and 
associates 18reported a 5-year survival of approxi- 
mately 17% among 136 patients with stage III 
disease treated primarily by transthoracic esopha- 
gectomy. Killinger and coworkers 2° reported a 10% 
5-year survival for 132 patients with stage III dis- 
ease, whereas Orringer, Marshall, and Stirling 21 
reported a 5-year survival rate of 12% for patients 
with similarly staged disease treated by transhiatal 
esophagectomy. On the other hand, the 34% 4-year 
survival reported here for patients with stage Ill 
disease after en bloc resection appears imilar to 
that reported by others who routinely employ 
equally radical techniques. Five-year survival for 
stage II! esophageal cancer after esophagectomy 
with two-field lymphadenectomy was reported by 
Akiyama and colleagues 16to be 38.5% and by Kato 
and associates 22to be 27%. 
Fourth, most randomized trials with either preop- 
erative chemotherapy or chemoradi0therapy have 
failed to show a survival advantage beyond that 
achieved by surgical intervention alone. 23-26 A re- 
cently reported randomized trial for patients with 
adenocarcinoma compared preoperative fluoroura- 
cil, cisplatin, and radiation of 40 Gy followed by 
resection with resection alone. 27 The 5-year survival 
in the combined-modality group was 32%, com- 
pared with 6% in the resection-alone arm. Although 
this was a statistically significant difference, the 
pretreatment s aging of both groups was limited. 
More significantly, the historical 5-year survival for 
surgical resection at that institution was 23%, a 
striking difference when compared with the results 
of the surgical arm of the study. 27 A recently con- 
cluded national multicenter study randomly as- 
signed patients to preoperative chemotherapy (flu- 
orouracil and cisplatin) versus resection alone. 28 
The preliminary results uggest no significant differ- 
ence between the two arms of the study. Clearly, the 
bulk of current evidence suggests that preoperative 
therapy combined with a standard resection has thus 
far produced no significant improvement in survival 
rates. These disappointing results have led some 
medical and radiation oncologists to question the 
relevance of surgical intervention in this disease, 
particularly since a 30% 5-year survival rate has 
been reported after chemoradiotherapy alone. 29 
There appears to be a dire need to reassess the current 
surgical strategies if one is to expect a change in this 
grim outlook. We believe that the salutary effect of 
radical resections, particularly with respect o node- 
positive disease and decreased local recurrence rates, 
may be a step in the right direction. 
Undoubtedly, the controversy regarding how 
"big" the procedure should be will continue. Some 
might suggest a randomized trial comparing radical 
and less radical surgical techniques. A randomized 
trial, however, can only compare potentially compa- 
rable strategies. The unquestionable deficiency of 
limited resections in providing adequate staging will 
not vanish in a randomized setting. This report, 
despite the relatively small number, comes close to 
what we believe is an adequate and fair assessment 
of the roles of both surgical techniques in the 
treatment of esophageal carcinoma. 
REFERENCES 
1. Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of 
oesophageal carcinoma. Br J Surg 1990;77:845-57. 
2. Gignoux M, Roussel A, Paillot B, et al. The value of 
preoperative radiotherapy in esophageal cancer: results of a 
study of the EORTC. World J Surg 1987;11:426-32. 
3, Naunheim KS, Petruska PJ, Roy TS, et al. Preoperative 
chemotherapy and radiotherapy for esophageal carcinoma. 
J Thorac Cardiovasc Surg 1992;5:887-95. 
4. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of 
adenocarcinoma of the esophagus and gastric ardia. JAMA 
1991;265:1287-9. 
5. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb rates 
of esophageal denocarcinoma: an update [letter]. JAMA 
1993;270:1320. 
6. Orringer MB, Sloan H. Esophagectomy without thoracot- 
omy. J Thorac Cardiovasc Surg 1978;76:643-54. 
7. Tilanus HW, Hop WC, Langenhorst BL, et al. Esophagec- 
tomy with or without thoracotomy: is there any difference? 
J Thorac Cardiovasc Surg 1993;105:898-903. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 6 
Altorki, Girardi, Skinner 9 5 5 
8. Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy 
by a transhiatal approach or thoracotomy: a prospective 
randomized trial. Br J Surg 1993;80:367-70. 
9. Skinner DB. Enbloc resection for neoplasms of the esopha- 
gus and cardia. J Thorac Cardiovasc Surg 1983;85:59-69. 
10. Hagen JA, Peters JH, DeMeester TR. Superiority of ex- 
tended en bloc esophagectomy for carcinoma of the lower 
esophagus and cardia. J Thorac Cardiovasc Surg 1993;106: 
850-8. 
11. Lerut T, De Leyn P, Coosemans W, et al. Surgical strategies 
in esophageal carcinoma with emphasis on radical lymphad- 
enectomy. Ann Surg 1992;216:583-90. 
12. Skinner DB, Little AG, Ferguson MK, Soriano A, et al. 
Selection of operation for esophageal cancer based on stag- 
ing. Ann Surg 1986;204:391-441. 
13. Zar J. Biostatistical nalysis, 2rid ed. Englewood Cliffs (NJ): 
Prentice Hall, 1984. p. 390. 
14. Brookmeyer R, Crowley J. A confidence interval for the 
median survival time. Biometrics 1982;38:29-42. 
15. Isono K, Sato HK, Nakayama K. Results of nationwide study 
on the three-field lymph node dissection of esophageal 
cancer. Oncology 1991;48:411-20. 
16. Akiyama H, Tsurumaru M, Udagawa H. Radical lymph node 
dissection for cancer of the thoracic esophagus. Ann Surg 
1994;220:364-73. 
17. Altorki NK, Skinner DB. Occult cervical nodal metastasis 
in esophageal cancer: preliminary results of three-field 
lymphadenectomy. J Thorac Cardiovasc Surg 1997;113: 
540-4. 
18. Lieberman MD, Schriver CD, Bleckner S, Butt M, et al. 
Carcinoma of the esophagus: prognostic significance ofhis- 
tologic type. J Thorac Cardiovasc Surg 1994;109:130-9. 
19. Kato H, Tachimori Y, Watanabe H, lizuki T, Terui S, 
Itabashi M, et al. Lymph node metastasis in the thoracic 
esophageal carcinoma. J Surg Oncol 1991;48:106-11. 
20. Killinger WA, Rice TW, Adelstein TW, Medendorp SV, et 
al. Stage II esophageal carcinoma: the significance ofT and 
N. J Thorac Cardiovasc Surg 1996;111:935-40. 
21. Orringer MB, Marshall B, Stirling MC. Transhiatal esopha- 
gectomy for benign and malignant disease. J Thorac Cardio- 
vasc Surg 1993;105:265-77. 
22. Kato H, Tachimori Y, Watanabe H, et al. Lymph node 
metastasis in thoracic esophageal carcinoma. J Surg Oncol 
1991;48:106-11. 
23. Roth JA, Pass HU, Flanagan MM, et al. Randomized clinical 
trials of preoperative and postoperative adjuvant chemother- 
apy with cisplatin, vindesine, and bleomycin for carcinoma of
the esophagus. J Tborac Cardiovasc Surg 1988;96:242-8. 
24. Schlag P. Randomisierte Studie zur praoperativen chemo- 
therapie beim plattenepithelcarcinom des oesophagus. 
Chirurg 1992;63:709-11. 
25. Kelsen DP, Minsky B, Smith M, et al. Preoperative therapy 
for esophageal cancer. A randomized comparison ofchemo- 
therapy versus radiation therapy. J Clin Oncol 1990;8:1352- 
61. 
26. Bosset JF, Gignoux M, Triboulet JP, et al. Randomised phase 
lII clinical trial comparing surgery alone versus pre-operative 
combined radiochemotherapy (XRT-CT) in stage I-II epi- 
dermoid cancer of the esophagus. Preliminary analysis: a
study of the FFCD (French group) No. 8805 and EORTC 
No. 40881 [abstract]. Proc Am Soc Clin Oncol 1994;13:197. 
27. Watsh TN, Noonan N, Hollywood D, Kelly A, et al. A 
comparison of multimodal therapy and surgery for esopha- 
geal adenocarcinoma. N Engl J Med 1996;35:462-7. 
28. Kelsen DP, Ginsburg R, Qian C, Gunderson L, et al. 
Chemotherapy followed by operation versus operation alone 
in the treatment ofpatients with localized esophageal cancer: 
a preliminary report of intergroup study 113 (RTOG 89-11) 
[abstract]. Meeting of the American Society of Clinical 
Oncology (ASCO), Denver. 1997. 
29. Herskovic A, Martz K, A1-Sarraf M, et al. Combined chemo- 
therapy and radiotherapy compared with radiotherapy alone 
in patients with cancer of the esophagus. N Engl J Med 
1992;326:1593-8. 
Discussion 
Dr. Victor F. Trastek (Rochester, Minn.). Dr. Altorki, I 
congratulate you on a fine presentation that further 
updates us on the results of en bloc esophagectomy. The 
treatment of esophageal carcinoma remains a challenge, 
and attempts at different forms of treatment, whether 
aimed at a local or a systemic approach, remain contro- 
versial. You pose the following question: Does extending 
the margins of resection radially and harvesting more 
lymph nodes improve survival in stage III disease? The 
data presented are interesting and compelling. The mor- 
tality rate of 5.4% is acceptable, morbidity remains ignif- 
icant, and survival is encouraging. However, without a 
prospective, randomized format, the question posed re- 
mains unanswered. You do call for such a study in your 
conclusion. When you design this study, I urge you to 
make comparisons between techniques on the basis of 
mortality, morbidity, survival at 5 years, quality of life, and 
costs. 
I have several questions: (1) Did the patients receive 
any other forms of therapy? If so, could this have influ- 
enced the results? (2) There were 87 patients who had 
cervical anastomoses. Was an en bloc approach used in 
the cervical area? (3) How do you currently manage 
patients who are found to have bulky lymphadenopathy 
on computed tomography or who have a positive lymph 
node found by ultrasonographically guided needle biopsy? 
I commend you on acquiring excellent results from an 
extensive operation and providing some light in what is 
usually a dark room. I look forward to your results from a 
prospective, randomized study. 
Dr, Mark Krasna (Baltimore, Md.). I too congratulate 
you and your colleagues on an excellent presentation a d 
excellent results. In a recent article from your group on 
the results of en bloc resection, you not only noted 
improved survival but also noted that the lymph node 
harvest was increased with this technique. 1 believe that in 
that recent paper on en bloc resection with three fields, 
you noted that the incidence of thoracic lymph node 
metastasis was 10 of 30 cases, actually lower than perhaps 
thought by Akiyama and others in the last decade, and 
most of the lymph node metastases were from either the 
supraclavicular dissection or the abdominal dissection. I 
wonder if you could point out for this group of patients 
with stage III disease with en bloc resection what percent- 
age had positive thoracic lymph nodes, versus either 
abdominal or cervical lymph nodes. 
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Dr. Altorki. Thank you for your comments. To answer 
Dr. Trastek's questions, adjuvant herapy in the form of 
preoperative chemotherapy was given to nine patients in 
this study, evenly distributed between the groups. Preop- 
erative radiation was never used. Postoperative radiation 
was not used for patients with NO disease, nor was 
postoperative chemotherapy. Patients with N1 disease 
received a "cocktail du jour" in terms of chemotherapy 
through the duration of the study, and almost everybody 
in both groups got it. To my knowledge, there is no 
evidence to date that shows a survival advantage from 
postoperative chemotherapy. 
We performed a neck anastomosis n 87 cases, but a 
neck dissection, as implied by the three fields, was only 
done in 32 cases. To date, our approach to patients with 
positive nodes, whether detected by ultrasonography or 
computed tomography, has primary been surgical resec- 
tion, in the belief that there are no data,  except perhaps 
for one study, that support the use of preoperative 
therapy. So our approach has been primary surgical 
resection. We are going to start an institutional study that 
involves preoperative chemotherapy followed by en bloc 
resection. 
To answer Dr. Krasna's question, what we have 
shown in the three-field study is that in patients with 
negative mediastinal and abdominal nodes, roughly 
20% of patients have positive nodes in the neck. 
Overall, among all patients, the prevalence of nodal 
metastasis n the thorax was about 30%. In this study, 
we did not specifically look at the distribution of nodal 
metastases, but I suspect it would be the same as that in 
our three-field issection. 
